Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

According to a SEC filing on Thursday, CEO Andrew Dudum sold 175,661 shares of the company for an aggregate value of about $11 million.

Shares of Hims & Hers Health are trading lower Friday morning after comments from President Donald Trump indicated that he expects the prices of popular weight-loss drugs to decrease.

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.8% in the afternoon session after a Bank of America analyst maintained a Sell rating on the stock, citing multiple concerns about the company's near-term performance. 

Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare.

New products are coming to the Hers platform.

The rally followed BofA Securities’ announcement that the new menopause and perimenopause service represents a multi-billion-dollar market opportunity for HIMS, supporting revenue diversification.

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31.

Investors liked what they heard about the company's latest expansion of its business.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 5.7% in the afternoon session after the company announced the launch of perimenopause and menopause treatment options on its platform. This expansion into women's health offered customers access to personalized treatment plans and prescription medications, including estradiol and progesterone. The treatments were made available in various forms such as pills, patches, and creams. The move was seen as a significant step for the company, which was reportedly on a path to achieve over $1 billion in annual revenue by 2026. By adding these hormone-replacement therapies, Hims & Hers broadened its services for its large subscriber base.

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company's launch of a new menopause and perimenopause care specialty on its Hers platform.

Shares are nearing a buy point out of a cup-with-handle base.

Investors looking at the healthcare industry have two excellent choices with UnitedHealth and Hims & Hers.

Discover how Hims & Hers Health (HIMS) combines explosive revenue growth with a bullish technical setup, making it a top telehealth stock to watch.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue forecast. 

HIMS stock shows strong technical momentum and a consolidation pattern, suggesting a potential breakout. The setup offers a clear risk/reward profile for technical traders.

Investors generally aren't fond of C-suite changes in relatively young businesses.

Hims & Hers (HIMS) is a high-growth momentum stock with strong earnings and a positive technical breakout setup, offering a compelling opportunity for investors.

A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.